GeoVax Labs, Inc. (GOVX): Price and Financial Metrics

GeoVax Labs, Inc. (GOVX): $0.79

-0.02 (-2.47%)

POWR Rating

Component Grades













Add GOVX to Watchlist
Sign Up

Industry: Biotech



in industry


  • Growth is the dimension where GOVX ranks best; there it ranks ahead of 49.01% of US stocks.
  • The strongest trend for GOVX is in Growth, which has been heading up over the past 173 days.
  • GOVX ranks lowest in Stability; there it ranks in the 1st percentile.

GOVX Stock Summary

  • The ratio of debt to operating expenses for GEOVAX LABS INC is higher than it is for about just 0.51% of US stocks.
  • With a price/sales ratio of 84.94, GEOVAX LABS INC has a higher such ratio than 97.53% of stocks in our set.
  • As for revenue growth, note that GOVX's revenue has grown -47.8% over the past 12 months; that beats the revenue growth of merely 3.88% of US companies in our set.
  • If you're looking for stocks that are quantitatively similar to GEOVAX LABS INC, a group of peers worth examining would be OPT, IMMP, ZYME, IVA, and HIMX.
  • Visit GOVX's SEC page to see the company's official filings. To visit the company's web site, go to

GOVX Valuation Summary

  • In comparison to the median Healthcare stock, GOVX's price/sales ratio is 4157.89% higher, now standing at 80.9.
  • GOVX's EV/EBIT ratio has moved up 212.8 over the prior 194 months.

Below are key valuation metrics over time for GOVX.

Stock Date P/S P/B P/E EV/EBIT
GOVX 2022-11-01 80.9 0.8 -1.1 0.4
GOVX 2022-10-31 84.1 0.8 -1.1 0.4
GOVX 2022-10-28 88.1 0.9 -1.2 0.3
GOVX 2022-10-27 87.4 0.9 -1.2 0.3
GOVX 2022-10-26 99.3 1.0 -1.4 0.2
GOVX 2022-10-25 78.0 0.8 -1.1 0.5

GOVX Growth Metrics

    Its 4 year revenue growth rate is now at 84.29%.
  • The 3 year cash and equivalents growth rate now stands at 8600.09%.
  • The 3 year price growth rate now stands at -100%.
Over the past 49 months, GOVX's revenue has gone down $465,060.

The table below shows GOVX's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-06-30 0.276902 -16.48367 -20.36272
2022-03-31 0.35661 -13.90863 -19.43505
2021-12-31 0.385501 -11.19642 -18.57032
2021-09-30 0.47216 -6.055222 -6.163836
2021-09-30 0.47216 -6.055222 -6.163836
2021-06-30 0.857204 -4.704643 -4.783981

GOVX's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • GOVX has a Quality Grade of D, ranking ahead of 16.15% of graded US stocks.
  • GOVX's asset turnover comes in at 0.054 -- ranking 535th of 563 Business Services stocks.
  • CELP, PGEN, and V are the stocks whose asset turnover ratios are most correlated with GOVX.

The table below shows GOVX's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.054 1 24.528
2021-03-31 0.110 1 5.871
2020-12-31 0.305 1 2.439
2020-09-30 0.525 1 1.312
2020-06-30 2.288 1 1.130
2020-06-30 2.288 1 1.130

GOVX Price Target

For more insight on analysts targets of GOVX, see our GOVX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $8.00 Average Broker Recommendation 1.5 (Moderate Buy)

GOVX Stock Price Chart Interactive Chart >

Price chart for GOVX

GOVX Price/Volume Stats

Current price $0.79 52-week high $4.91
Prev. close $0.81 52-week low $0.55
Day low $0.78 Volume 251,800
Day high $0.80 Avg. volume 9,155,694
50-day MA $0.95 Dividend yield N/A
200-day MA $1.31 Market Cap 20.78M

GeoVax Labs, Inc. (GOVX) Company Bio

GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and cancers using modified vaccinia ankara virus-like particle vaccine platform in the United States and internationally. It is developing various preventive vaccines against coronavirus (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for chronic Hepatitis B infections and cancers. The company has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; the HIV Vaccines Trial Network; Centers for Disease Control and Prevention; U.S. Department of Defense; U.S. Army Research Institute of Infectious Disease; U.S. Naval Research Laboratory; Emory University; University of Pittsburgh; Georgia State University Research Foundation; University of Texas Medical Branch; the Institute of Human Virology at the University of Maryland; the Scripps Research Institute; the Burnet Institute; American Gene Technologies International, Inc.; Viamune, Inc.; Vaxeal Holding SA; Virometix AG; Geneva Foundation; Enesi Pharma; UCSF; BravoVax; and Leidos, Inc. GeoVax Labs, Inc. was founded in 2001 and is based in Smyrna, Georgia.

GOVX Latest News Stream

Event/Time News Detail
Loading, please wait...

GOVX Latest Social Stream

Loading social stream, please wait...

View Full GOVX Social Stream

Latest GOVX News From Around the Web

Below are the latest news stories about GEOVAX LABS INC that investors may wish to consider to help them evaluate GOVX as an investment opportunity.

H.C. Wainwright Keeps Their Buy Rating on GeoVax Labs (GOVX)

H.C. Wainwright analyst Vernon Bernardino reiterated a Buy rating on GeoVax Labs (GOVX - Research Report) today and set a price target of $8.00. The company's shares closed yesterday at $0.77.Bernardino covers the Healthcare sector, focusing on stocks such as Geron, Artelo Biosciences, and Cassava Sciences. According to TipRanks, Bernardino has an average return of 19.4% and a 32.49% success rate on recommended stocks. Currently, the analyst consensus on GeoVax Labs is a Moderate Buy with an average price target of $5.50, representing a 612.34% upside. In a report released yesterday, Maxim Group also maintained a Buy rating on the stock with a $3.00 price target.

Christine Brown on TipRanks | November 11, 2022

GeoVax Labs Third Quarter 2022 Earnings: US$0.17 loss per share (vs US$0.31 loss in 3Q 2021)

GeoVax Labs ( NASDAQ:GOVX ) Third Quarter 2022 Results Key Financial Results Net loss: US$3.97m (loss widened by 103...

Yahoo | November 11, 2022

GeoVax Reports 2022 Third Quarter Financial Results and Provides Corporate Update

Phase 2 Clinical Trials Advance for COVID-19 and Immuno-Oncology Company Secures Rights to NIH-MVA for Protection Against Monkeypox and Smallpox ATLANTA, GA, Nov. 09, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced its financial results for the third quarter ended September 30, 2022. GeoVax’s management will host a live conference call and webcast

Yahoo | November 9, 2022

Will GeoVax Labs (NASDAQ:GOVX) Spend Its Cash Wisely?

We can readily understand why investors are attracted to unprofitable companies. For example, although...

Yahoo | October 31, 2022

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

It's time to start off the day with a breakdown of the biggest pre-market stock movers for Wednesday morning and the latest news!

William White on InvestorPlace | October 26, 2022

Read More 'GOVX' Stories Here

GOVX Price Returns

1-mo -19.12%
3-mo -34.17%
6-mo N/A
1-year -83.16%
3-year -97.18%
5-year -100.00%
YTD -78.18%
2021 7.10%
2020 -71.83%
2019 -100.00%
2018 -52.00%
2017 -19.35%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.6393 seconds.